Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. by Galiè, N et al.
  	

Tadalafil in Idiopathic or Heritable Pulmonary Arterial Hypertension (PAH)
Compared to PAH Associated with Connective Tissue Disease
Nazzareno Galie`, Christopher P. Denton, Fabio Dardi, Alessandra Manes,
Gaia Mazzanti, Baohui Li, Lucio Varanese, Anne Esler, Cathi Harmon,
Massimiliano Palazzini
PII: S0167-5273(17)31124-5
DOI: doi:10.1016/j.ijcard.2017.02.094
Reference: IJCA 24620
To appear in: International Journal of Cardiology
Received date: 18 August 2016
Revised date: 13 January 2017
Accepted date: 20 February 2017
Please cite this article as: Galie` Nazzareno, Denton Christopher P., Dardi Fabio, Manes
Alessandra, Mazzanti Gaia, Li Baohui, Varanese Lucio, Esler Anne, Harmon Cathi,
Palazzini Massimiliano, Tadalaﬁl in Idiopathic or Heritable Pulmonary Arterial Hyper-
tension (PAH) Compared to PAH Associated with Connective Tissue Disease, Interna-
tional Journal of Cardiology (2017), doi:10.1016/j.ijcard.2017.02.094
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Title:  Tadalafil in Idiopathic or Heritable Pulmonary Arterial Hypertension (PAH) 
Compared to PAH Associated with Connective Tissue Disease 
Authors:  Nazzareno Galiè1, Christopher P. Denton2, Fabio Dardi3, Alessandra 
Manes4, Gaia Mazzanti5, Baohui Li6, Lucio Varanese7, Anne Esler8, Cathi 
Harmon9, Massimiliano Palazzini10 
Corresponding Author: 
Professor Nazzareno Galiè,  
Department of Experimental, Diagnostic and Specialty Medicine (DIMES),  
University of Bologna, via Massarenti 9, 
40138-Bologna, Italy 
Tel: +39 051 349 858 
Fax: +39 051 344 859 
Email: nazzareno.galie@unibo.it 
Affiliations and Authorship 
1Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 
University of Bologna, Bologna, Italy. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation.  During the conduct of the study, Dr. Galiè reports 
grants and personal fees from Eli Lilly and Company, grants and personal fees 
from Actelion, grants and personal fees from GSK, grants and personal fees from 
Bayer, grants and personal fees from Pfizer. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2Centre for Rheumatology at the Royal Free and University College Medical 
School, Hampstead, London. This author takes responsibility for all aspects of 
the reliability and freedom from bias of the data presented and their discussed 
interpretation.  Outside the submitted work, Dr. Denton reports personal fees 
from Actelion Pharmaceuticals, personal fees from GSK, grants from Actelion 
Pharmaceuticals, personal fees from Bayer. 
3Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 
University of Bologna, Bologna, Italy. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. Dr. Dardi has nothing to disclose. 
4Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 
University of Bologna, Bologna, Italy. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. Dr. Manes has nothing to disclose. 
5Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 
University of Bologna, Bologna, Italy. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. Dr. Mazzanti has nothing to disclose. 
6Eli Lilly and Company, Indianapolis, IN, USA. This author takes responsibility for 
all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation.  Dr. Li has nothing to disclose. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
7Eli Lilly and Company, Indianapolis, IN, USA. This author takes responsibility for 
all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation.  Dr. Varanese has nothing to disclose. 
8inVentiv Clinical Solutions, LLC, Indianapolis, IN, USA. This author takes 
responsibility for all aspects of the reliability and freedom from bias of the data 
presented and their discussed interpretation. Dr. Esler has nothing to disclose. 
9Eli Lilly and Company, Indianapolis, IN, USA. This author takes responsibility for 
all aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation.  Mrs. Harmon has nothing to disclose. 
10Department of Experimental, Diagnostic and Specialty Medicine (DIMES), 
University of Bologna, Bologna, Italy. This author takes responsibility for all 
aspects of the reliability and freedom from bias of the data presented and their 
discussed interpretation. Dr. Palazzini has nothing to disclose. 
 
Keywords: Associated PAH, PHIRST, PHIRST-2, idiopathic, heritable   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Abstract    
 
Background 
The primary objective of this post hoc analysis was to evaluate clinical outcomes 
of tadalafil in patients with pulmonary arterial hypertension (PAH) associated with 
connective tissue disease (CTD-PAH) compared with patients with 
idiopathic/heritable PAH (I/H-PAH) for primary and key secondary efficacy 
endpoints, and safety.  This analysis included adult patients with CTD-PAH or 
I/H-PAH who participated in the PHIRST and PHIRST-2 studies.     
Methods 
Patients were randomized 1:1:1:1:1 to tadalafil (2.5, 10, 20, or 40 mg) or placebo 
in the PHIRST study and the majority of these patients were subsequently 
assigned 40 mg in PHIRST-2. Patients taking 20 mg in PHIRST without 
demonstrating clinical worsening continued on 20 mg in PHIRST-2.  Outcomes 
analyzed included 6MWD, WHO-FC, and incidence and time to first occurrence 
of clinical worsening.  Safety was assessed through evaluation of adverse events 
(AEs), clinical laboratory data, electrocardiograms, and physical examinations. 
Results  
Increased 6MWD in PHIRST was maintained in both CTD-PAH and I/H-PAH 
subgroups for 52 weeks.  Patients with CTD-PAH tended to be older, were more 
likely female, had lower exercise capacity, were more likely to have clinical 
worsening, and experienced AEs more frequently than patients with I/H-PAH.   
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Conclusion 
The effect of tadalafil treatment in patients enrolled in both PHIRST studies was 
detectable for both I/H-PAH and CTD-PAH subgroups.  In general, subgroup 
differences were modest.  Patients with CTD-PAH may perform less well than 
patients with I/H-PAH in safety and efficacy measures in all treatment groups, 
which is similar to other studies demonstrating a worse prognosis for patients 
with CTD-PAH.  
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1. Introduction 
Pulmonary arterial hypertension (PAH) is a severe and chronic disease 
characterized by a progressive obstructive remodeling of the distal pulmonary 
arteries which results in increased pulmonary vascular resistance and pressure.  
PAH includes a heterogeneous group of clinical entities:  idiopathic PAH (IPAH), 
heritable PAH (HPAH), drug and toxin induced PAH, and PAH associated with 
other conditions such as, connective tissue disease (CTD-PAH) [1]. 
When considering the entire adult PAH population, it has been estimated 
that up to 30% suffer from CTD-PAH [2], the second largest patient subgroup 
after IPAH.  Patients with CTD-PAH have been included in many of the 
randomized controlled trials and adequately represent the subgroup as it occurs 
in the general PAH population.  Previous studies suggest that CTD-PAH patients 
have a worse prognosis than other PAH subgroups and that patients with PAH 
associated with the scleroderma spectrum of diseases have a particularly poor 
outcome [3]. 
The Pulmonary Arterial HypertensIon and ReSponse to Tadalafil (PHIRST) 
study was a 16-week, double-blind, placebo-controlled study evaluating 4 doses 
of tadalafil (an oral, once-daily phosphodiesterase [PDE]-5 inhibitor) [4].  
Significant improvement as compared with placebo (PBO) was seen in the 
highest dose studied (40 mg), for six-minute walk distance (6MWD), time to 
clinical worsening (TTCW) and quality of life [4].  The approved dose of tadalafil 
for PAH treatment in adults is 40 mg [4]. After participating in the PHIRST trial, 
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eligible patients were enrolled in a 52-week, double-blind, multicenter, long-term 
prospective extension study (PHIRST-2) and received either tadalafil 20 mg 
(T20) or 40 mg (T40) [5]. The increased 6MWD observed in both T20 and T40 
groups in PHIRST was also maintained during PHIRST-2 [5]. 
This study reports the result of a post hoc analysis of PHIRST and 
PHIRST-2 data in order to evaluate the effect of tadalafil treatment in the subset 
of patients with CTD-PAH as compared to the subset of patients with 
idiopathic/heritable PAH (I/H PAH). 
2. Methods  
2.1 Patients 
Patient eligibility for the PHIRST and PHIRST-2 studies has been 
previously reported [4,5].  This post hoc analysis includes the subset of patients 
with CTD-PAH or I/H PAH who were randomized in the PHIRST study and 
transitioned to the PHIRST-2 extension study [5].   
Both PHIRST study protocols were approved by local institutional review 
boards or independent ethics committees, and written informed consent (or 
assent when appropriate) was obtained from all patients.  The PHIRST and 
PHIRST-2 studies were conducted in full compliance with the principles of the 
Declaration of Helsinki, the International Conference on Harmonisation 
guidelines, or with the laws and regulations of the country in which the research 
was conducted, whichever afforded the greater protection to the study subject. 
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The primary objective of this post hoc analysis was to evaluate some of the 
efficacy and safety endpoints of tadalafil in patients with CTD-PAH as compared 
with patients with I/H PAH.   The detailed designs of both  PHIRST and PHIRST-
2 studies have previously been reported [4,5]. 
In the PHIRST study, patients with PAH were randomized 1:1:1:1:1 to tadalafil 
2.5 mg (T2.5), tadalafil 10 mg (T10), tadalafil 20 mg (T20), tadalafil 40 mg (T40), 
or PBO for 16 weeks [4].   Thereafter, eligible patients from PHIRST were 
enrolled in PHIRST-2 and assigned to continue T20 or to receive T40 for 52 
weeks.  Patients who received tadalafil T20 in PHIRST without clinical worsening 
(CW) continued to receive T20 (T20/T20), patients who received T40 in PHIRST 
continued on T40 (T40/T40), and patients who previously received tadalafil T2.5, 
T10, or T20 (with CW) in PHIRST switched to T40 (T2.5-T20/T40).  This analysis 
for the PHIRST study includes patients receiving PBO, T20, and T40; analysis for 
the PHIRST-2 study includes data for all patients who entered PHIRST-2.  
Of note, patients were able to enter PHIRST while on background 
bosentan (125 mg twice daily) and continue on bosentan during PHIRST-2.  
Patients were discontinued from both studies if they began a new PAH-specific 
therapy such as prostanoids, other PDE-5 inhibitors and/or an endothelin 
receptor antagonist (ERA) [4,5]. 
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2.2 Statistical methods 
The PHIRST and PHIRST-2 studies were not powered to examine efficacy 
or safety differences within subgroups. Therefore, reported differences are 
descriptive and should be regarded as exploratory. 
Within the etiology subgroups of I/H PAH and CTD-PAH, summaries are 
presented for patients randomized to PBO, T20 or T40 in PHIRST and all 
patients who continued in PHIRST-2.   
The PHIRST baseline was defined as the pre-randomization period.  
PHIRST-2 baseline for 6MWD and World Health Organization Functional Class 
(WHO-FC) was determined using data obtained from the end of PHIRST.  Other 
PHIRST-2 baseline demographics were established by the baseline demographic 
characteristics from the PHIRST screening visit. 
Outcomes analyzed from the start of PHIRST through the end of PHIRST-
2 included 6MWD, WHO-FC and incidence of, and time to first occurrence of 
CW. Continuous variables are presented as mean ± standard deviation (SD) and 
categorical variables are summarized as counts and percentages.  
To examine changes in 6MWD over time, mean 6MWD at each visit in 
PHIRST and PHIRST-2 was plotted by treatment group within each etiology 
subgroup. The proportion of the relationship between TTCW in PHIRST or 
PHIRST-2 and etiology was examined using Cox proportional hazard models for 
those patients who received T20 or T40 in PHIRST. In addition, Kaplan-Meier 
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estimates of the proportion of patients experiencing CW and remaining at risk at 
each PHIRST-2 visit were displayed graphically. 
Adverse events (AEs) reported in PHIRST-2 were summarized as the 
number and percentage in each treatment group reporting the specific category 
of event; baseline for the definition of treatment-emergent adverse events 
(TEAEs) was the run-in period prior to randomization in PHIRST. 
 
2.3 Outcome measures 
Durability of efficacy was assessed by measuring 6MWD.  WHO-FC and 
CW events were collected in both studies.  WHO-FC was determined by the local 
investigator.  Clinical worsening events were reported by investigators as any 
occurrence of death, lung or heart-lung transplantation, atrial septostomy, the 
start of any new chronic treatment for PAH, worsening WHO-FC, or worsening 
PAH requiring hospitalization. 
Safety was assessed for both studies through evaluation of AEs, clinical 
laboratory data, electrocardiograms, and physical examinations.  Treatment-
emergent adverse events were those events that first ensued or increased in 
intensity after baseline (the run-in period before randomization in the 16-week 
PHIRST study). 
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3. Results  
While multiple tadalafil doses were studied in PHIRST, this subgroup 
analysis only includes data from patients with I/H-PAH (n=150) on PBO (n=54), 
T20 (n=50) and T40 (n=46), and patients with CTD-PAH (n=56) on PBO (n=16), 
T20 (n=21) and T40 (n=19).  
In PHIRST-2, 4 treatment groups were analyzed for the I/H-PAH (n=223) 
and CTD-PAH (n=78) subgroups, respectively: T20/T20 (n=37, n=16), T40/T40 
(n=43, n=13), T2.5-T20/T40 (n=94, n=34), and PBO/T40 (n=49, n=15). 
3.1 Baseline Demographics 
Baseline demographics of patients with CTD-PAH and I/H-PAH enrolled in 
the PHIRST and PHIRST-2 studies are reported in Table 1.  Patients with CTD-
PAH were more likely to be female, and had a mean age that was slightly higher 
than patients with I/H-PAH in all treatment groups summarized.  
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Table 1: Baseline Demographic, Clinical and Exercise Characteristics, and Percent of 
Bosentan use in I/H-PAH and CTD-PAH Patients Enrolled in the PHIRST and PHIRST-2 
Studies. 
 
Characteristi
c 
PHIRST (baseline)
a
 PHIRST-2 (baseline) 
I/H-PAH (N=150) CTD-PAH (N=56) I/H-PAH (N=223) 
 
CTD-PAH (N=78) 
 
PBO 
(n=54
) 
T20 
(n=50) 
 
T40 
(n=46
) 
 
PBO 
(n=16
) 
 
T20 
(n=21
) 
 
T40 
(n=19
) 
 
T20/T2
0 
(n=37) 
 
PBO/T4
0 (n=49) 
 
T2.5-
T20/T4
0 
(n=94) 
 
T40/T4
0 
(n=43) 
 
T20/T2
0 
(n=16) 
 
PBO/T4
0 (n-15) 
 
T2.5-
T20/T4
0 
(n=34) 
 
T40/T4
0 
(n=13) 
Age (years), 
mean (SD) 57 (15) 54 (15) 54 (15) 59 (13) 55 (15) 56 (14) 55 (15) 56 (15) 55 (16) 53 (15) 55 (13) 60 (14) 58 (13) 61 (14) 
Sex, n (% 
female) 40 (74) 36 (72) 30 (65) 15 (94) 18 (86) 16 (84) 28 (76) 37 (76) 68 (72) 29 (67) 13 (81) 14 (93) 32 (94) 11 (85) 
6MWD 
(meters), 
mean (SD) 
337 
(87) 346 (73) 
362 
(79) 
347 
(79) 
317 
(85) 
327 
(79) 405 (73) 370 (98)
b
 377 (91)
c
 408 (77) 375 (73) 321 (110) 333 (99) 380 (108) 
WHO-FC, n 
(%):               
  Class I 0 0 1(2) 0 0 1 (5) 2 (5) 1 (2) 3 (3) 2 (5) 2 (12) 0 2 (6) 1 (8) 
  Class II 17 (31) 13 (26) 16 (35) 5 (31) 9 (43) 5 (26) 24 (65) 24 (49) 45 (48) 24 (56) 11 (69) 5 (33) 8 (24) 6 (46) 
  Class III 35 (65) 37 (74) 29 (63) 11 (69) 12 (57) 13 (68) 11(30) 21 (43) 37 (39) 17 (40) 3 (19) 7 (47) 21 (62) 6 (46) 
  Class IV 2 (4) 0 0 0 0 0 0 3 (6) 9 (10) 0 0 3 (20) 3 (9)
d
 0 
Bosentan 
use, n  (% 
yes) 31 (57) 25 (50) 22 (48) 8 (50) 12 (57) 11 (58) 21 (57) 29 (59) 43 (46) 21 (49) 9 (56) 7 (47) 23 (68) 8 (62) 
 
Abbreviations: I/H-PAH - idiopathic/heritable pulmonary arterial hypertension; CTD-PAH - pulmonary arterial hypertension associated with connective tissue disease; N - total 
number of patients included in analysis; n - total number of patients in each treatment arm analyzed 
 
6MWD - 6 minute walk distance; T20/T20 - tadalafil 20 mg in PHIRST and PHIRST-2; PBO/T40 - placebo in PHIRST, tadalafil 40 mg in PHIRST-2; T2.5-20/T40 - tadalafil 2.5 
mg to 20 mg in PHIRST, tadalafil 40 mg in PHIRST-2;T40/T40 - tadalafil 40 mg in PHIRST and PHIRST-2; SD - standard deviation; WHO-FC - World Health Organization 
Functional Class 
 
a
2.5 and 10 mg data not shown; 
b
2 patients missing baseline value; 
c
4 patients missing baseline value;  
d
Numbers do not add up to 100 due to rounding 
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3.2 Exercise Characteristics (6MWD) 
Consistent with the overall efficacy results previously reported for PHIRST 
[4], the greatest increases in 6MWD from baseline during PHIRST were seen in 
the T20 and T40 treatment arms in both the CTD-PAH and I/H-PAH subgroups.  
In the PBO group there was no improvement in 6MWD in patients with CTD-
PAH, while patients with I/H-PAH showed modest improvement (Figure 1).   
The increase seen in 6MWD at the end of PHIRST was maintained in both 
the CTD-PAH and I/H-PAH subgroups for 52 weeks.  While improvements in 
6MWD were seen in both subgroups, patients receiving PBO or lower doses of 
tadalafil in PHIRST and switched to T40 in PHIRST-2 had lower 6MWD at the 
end of PHIRST-2 than those patients who started and stayed on T20 or T40 
throughout both studies (Figure 1).  
3.3 WHO-FC 
In the PHIRST study, a higher percentage of patients with CTD-PAH 
worsened in WHO-FC status than patients with I/H-PAH in the PBO, T20 and 
T40 treatment arms (Table 2). 
For patients who were on T40 in both PHIRST and PHIRST-2, 7% with I/H-
PAH and 15% with CTD-PAH had worsened WHO-FC. Improved WHO-FC was 
seen in 10% of those patients with I/H-PAH and 15% with CTD-PAH (Table 2).   
For both etiologies, there were numerically higher proportions of patients 
with worsened WHO-FC in the T20 group than the T40 group in the PHIRST 
study and in the T20/20 group than the T40/40 group in PHIRST-2 (Table 2). 
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Table 2: Change in WHO-FC by Treatment Group and Etiology for PHIRST and PHIRST-2 
Studies  
Condition 
Change from baseline to Week 16 (PHIRST) Change from baseline to endpoint (PHIRST-2) 
I/H PAH (N=150) CTD-PAH (N=56) I/H PAH (N=223
a
) CTD-PAH (N=78
b
) 
 PBO 
n=53 
T20 
n=50 
T40 
n=46 
PBO 
n=16 
T20 
n=19 
T40 
n=18 
T20/T20 
n=37 
PBO/T40 
n=48 
T2.5-T20/T40 
n=90 
T40/T40 
n=41 
T20/T20 
n=15 
PBO/T40 
n=14 
T2.5-T20/T40 
n=34 
T40/T40 
n=13 
Worsened, n (%) 5 (9) 4 (8) 1 (2) 4 (25) 2 (11) 1 (6) 8 (22) 2 (4) 8 (9) 3 (7) 3 (20) 2 (14) 2 (6) 2 (15) 
No change, n (%) 35 (66) 28 (56) 35 (76) 10 (62) 9 (47) 13 (72) 23 (62) 36 (75) 64 (71) 34 (83) 12 (80) 10 (71) 26 (77) 9 (69) 
Improved, n (%) 13 (25) 18 (36) 10 (22) 2(12)
c
 8 (42) 4 (22) 6 (16) 10 (21) 18 (20) 4 (10) 0 (0) 2 (14) 6 (18) 2 (15) 
 
Abbreviations: I/H-PAH - idiopathic/heritable pulmonary arterial hypertension; CTD-PAH - pulmonary arterial hypertension associated with connective tissue disease; N - total 
number of patients included in analysis; n - total number of patients in each treatment arm analyzed 
 
a
Data was only available for 216 patients at endpoint; 
b
Data was only available for 76 patients at endpoint; 
c
Please note the percentages do not add up to 100% due to 
rounding.  
 
3.4 Clinical Worsening 
Kaplan-Meier estimates of the proportion of patients experiencing CW at 
Week 16 of the PHIRST study demonstrated that CTD-PAH patients were more 
likely to experience CW (T40: n=2, 11%; PBO: n=4, 25%)  compared to I/H-PAH 
patients (T40: n=2, 4%; PBO: n=8, 15%) (Figure 2).   
In the 52-week PHIRST-2 study, 33% of patients with CTD-PAH and 14% 
of patients with I/H-PAH who had moved from PBO to T40 had experienced CW 
by Week 52. For patients who remained on T40, 46% of those with CTD-PAH 
had CW compared with 14% of those with I/H-PAH (data on file). 
Combined data for patients with I/H-PAH taking T20 and T40 revealed a 
lower incidence of CW and a longer time to first event of CW than patients with 
CTD-PAH over 68 weeks (PHIRST and PHIRST-2 studies).  The Kaplan-Meier 
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analyses of time to first event of CW in patients with I/H-PAH and CTD-PAH in 
the 68-week period are reported in Figure 3. 
3.5 Safety 
While AEs had a similar profile between groups in PHIRST, patients with 
CTD-PAH tended to have a higher frequency of AEs than patients with I/H-PAH. 
In the PHIRST-2 study, patients with CTD-PAH had a similar frequency of 
at least one TEAE than patients with I/H-PAH (94% and 92% respectively), with 
headache being the most indicated AE.  In addition, patients with CTD-PAH had 
a numerically higher rate of serious AEs (SAEs) including death, than patients 
with I/H-PAH (40% and 22% respectively) (data on file).   
TEAEs occurring in >15% of patients on tadalafil in PHIRST and PHIRST-2 
are shown in Table 3 and Table 4 respectively.  
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Table 3: TEAEs Occurring in Greater than 15 Percent of Tadalafil Patients by Etiology in 
the 16-week PHIRST Study 
 
 PHIRST 
Adverse Event Preferred Term, n (%) I/H PAH CTD-PAH 
 PBO N=54 T20 N=50 T40 N=46 PBO N=16 T20 N=21 T40 N=19 
Headache 6 (11) 11 (22) 16 (35) 2 (12) 6 (29) 10 (53) 
Diarrhea 6 (11) 3 (6) 4 (9) 1 (6) 3 (14) 5 (26) 
Nausea 4 (7) 3 (6) 3 (6) 0 5 (24) 4 (21) 
Back pain 3 (6) 4 (8) 6 (13) 2 (12) 5 (24) 2 (10) 
Myalgia 0 4 (8) 6 (13) 3 (19) 1 (5) 4 (21) 
Dizziness 2 (4) 2 (4) 2 (4) 4 (25) 2 (10) 4 (21) 
Vomiting 1 (2) 1 (2) 0 0 4 (19) 2 (10) 
Dyspepsia 1 (2) 8 (16) 6 (13) 0 1 (5) 1 (5) 
Pulmonary hypertension 3 (6) 7 (14) 3 (6) 4 (25) 0 3 (16) 
Edema – peripheral 3 (6) 4 (8) 2 (4) 4 (25) 2 (10) 3 (16) 
Nasal congestion 0 0 4 (9) 1 (6) 0 3 (16) 
Flushing 0 4 (8) 7 (15) 1 (6) 0 1 (5) 
 
Abbreviations: I/H-PAH - Idiopathic/heritable pulmonary arterial hypertension; CTD-PAH - pulmonary arterial hypertension associated with connective tissue disease; PBO - 
placebo; N=total randomized patients in treatment group; n=number of patients with adverse event preferred term 
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Table 4: TEAEs Occurring in Greater than 15 Percent of Tadalafil Patients by Etiology in 
the 52-week PHIRST-2 Study 
 
Adverse Event Preferred Term, n (%) 
PHIRST-2 
I/H PAH CTD-PAH 
 
T20/T20 
N=37 
PBO/T40 
N=49 
T2.5-
20/T40 
N=94 
T40/T40 
N=43 
T20/T20 
N=16 
PBO/T40 
N=15 
T2.5-
20/T40 
N=34 
T40/T40 
N=13 
Headache 4 (11) 16 (33) 23 (25) 6 (14) 2 (13) 3 (20) 10 (29) 2 (15) 
Back pain 2 (5) 9 (18) 9 (10) 7 (16) 0 3 (20) 7 (21) 0 
Nasopharyngitis 5 (14) 9 (18) 8 (9) 5 (12) 0 0 1 (3) 0 
Dyspnea 3 (8) 4 (8) 10 (11) 8 (19) 1 (6) 1 (7) 3 (9) 1 (8) 
Edema – peripheral 3 (8) 2 (4) 12 (13) 5 (12) 2 (13) 4 (27) 7 (21) 1 (8) 
Upper respiratory tract infection 4 (11) 1 (2) 9 (10) 7 (16) 0 4 (27) 2 (6) 3 (23) 
Fatigue 1 (3) 1 (2) 7 (7) 6 (14) 0 2 (13) 1 (3) 3 (23) 
Cough 5 (14) 2 (4) 2 (2) 4 (9) 0 5 (33) 4 (12) 2 (15) 
 
Abbreviations: I/H-PAH - Idiopathic/heritable pulmonary arterial hypertension; CTD-PAH - pulmonary arterial hypertension associated with connective tissue disease; PBO - 
placebo; N=total randomized patients in treatment group; n=number of patients with adverse event preferred term 
 
4. Discussion 
This is the first analysis to compare the effects of tadalafil in the 2 largest 
subgroups of PAH (I/H-PAH and CTD-PAH) in studies where approximately 50% 
of the patient population was on background therapy with bosentan. 
Patients with CTD-PAH tended to be older, were more likely to be female, 
had a lower exercise capacity, were more likely to have CW, and experienced 
AEs more frequently than patients with I/H-PAH. 
The treatment effect on 6MWD observed with tadalafil was similar among 
the CTD-PAH and I/H-PAH groups in the PHIRST study. This is in contrast with 
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the smaller effect observed in patients with CTD-PAH as compared with patients 
with I/H-PAH in other randomized controlled studies in PAH [6].  This apparently 
larger effect of tadalafil in CTD-PAH as compared to other studies should be 
confirmed by specific studies to exclude an effect due to spontaneous variability.  
Both patients with CTD-PAH and I/H-PAH who were on PBO or on lower 
doses (T2.5 and T10) of tadalafil in PHIRST and then transitioned to T40 in 
PHIRST-2 did not improve as well as those who started and stayed on T20 or 
T40 throughout both studies. This may suggest that patients with CTD-PAH and 
I/H-PAH could benefit from efficacious therapy as early as possible in the clinical 
course. 
In both subgroups, the increase in exercise capacity at the end of the 16-
week PHIRST study was maintained for 52 weeks, but improved more in patients 
randomized initially to T20 or T40 as compared with those randomized to PBO, 
T2.5, T10 or T20 with a worsening event. This may confirm the need to start the 
effective dose of tadalafil as soon as possible because a delay may result in a 
lower effect on exercise capacity. However, the PHIRST baseline values of 
6MWD in patients receiving PBO or lower doses of tadalafil in PHIRST appear to 
be lower and this may have influenced their final absolute value at the end of 
PHIRST-2. 
In PHIRST and PHIRST-2 studies, numerically higher proportions of 
patients with CTD-PAH worsened in WHO-FC as compared to patients with I/H-
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PAH. This is consistent with the higher rate of progression of PAH in patients 
with CTD. 
In the PHIRST study, TTCW events were numerically higher in the PBO 
group as compared to the T40 group in both I/H-PAH and CTD-PAH groups. In 
the PHIRST-2 analysis, TTCW events were numerically higher in CTD-PAH than 
in I/H-PAH across all treatment groups, except T2.5-T20/T40.  The lack of a PBO 
group in the PHIRST-2 study does not allow us to analyze the relative reduction 
of TTCW events, if any, in the I/H-PAH and CTD-PAH groups. Over 68 weeks, 
TTCW was more delayed in patients with I/H-PAH than in patients with CTD-
PAH.  
These data support the worse prognosis of patients with CTD-PAH as 
compared with I/H-PAH and as observed in registry data [7,8]. 
The reasons for these findings may include the older age of patients with 
CTD-PAH, the presence of comorbidities, and/or a lower efficacy of PAH-
approved treatments on the outcome of patients with CTD-PAH as observed in 
other studies [9]. 
During long-term treatment, patients with CTD-PAH had a numerically 
higher rate of SAEs, including death, than patients with I/H-PAH.  The TEAE 
profile was similar for both subgroups. These data confirm the worse general 
clinical profile of patients with CTD-PAH as compared to those with I/H-PAH. 
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4.1 Study Limitations 
 Overall, this subgroup analysis indicates long-term treatment with tadalafil 
was well tolerated in patients with I/H-PAH and CTD-PAH. All differences in the 
baseline demographics and treatment effects are described numerically and 
cannot be substantiated by a statistical test as the PHIRST and PHIRST-2 
studies were insufficiently powered to examine efficacy or safety within 
subgroups. Some patients participating in the PHIRST study did not elect to 
continue in the long-term extension period, and patients on T40 with CW were 
not eligible to transition to PHIRST-2.  In addition, some patients discontinued 
early from the studies and therefore survival results are not available for these 
patients. The missing data of these patients may have influenced the study 
results. 
Data from the PHIRST-2 study should be interpreted with caution given the 
lack of a PBO control and a slightly higher percentage (60%) of CTD-PAH 
patients on background bosentan compared to I/H-PAH patients (51%). 
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5. Conclusion 
In summary, the PHIRST study demonstrated that patients with I/H-PAH 
and CTD-PAH receiving 40 mg tadalafil experienced favorable results on 
exercise capacity.  While subgroup differences overall were generally small in the 
PHIRST-2 study, patients with CTD-PAH tended to perform less well in clinical 
and safety measures in all treatment groups, consistent with a worse outcome for 
these patients. Since patients with CTD-PAH who transitioned from suboptimal 
doses in PHIRST to T40 in PHIRST-2 showed less improvement than those who 
remained on T20 and T40 during both trials, it suggests that earlier use of 
effective dosing is advantageous. 
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Figures: 
 
Figure 1 
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Figure 2 
 
 
 
  
I/H-PAH CTD-PAH
Day 28
(4 weeks)
Day 56
(8 weeks)
Day 84
(12 weeks)
Day 112
(16 weeks)
Treatment group At risk CW At risk CW At risk CW At risk CW
I/H-PAH (N=150)
PBO, n (%)
20 mg, n (%)
40 mg, n (%)
51 (94)
50 (100)
45 (98)
3 (6)
0
1 (2)
48 (89)
47 (94)
45 (98)
5 (9)
1 (2)
1 (2)
45 (83)
43 (86)
45 (98)
8 (15)
4 (8)
1 (2)
20 (37)
28 (56)
33 (72)
8 (15)
6 (12)
2 (4)
Day 28
(4 weeks)
Day 56
(8 weeks)
Day 84
(12 weeks)
Day 112
(16 weeks)
Treatment group At risk CW At risk CW At risk CW At risk CW
CTD-PAH (N=56)
PBO, n (%)
20 mg, n (%)
40 mg, n (%)
15 (94)
16 (76)
17 (89)
1 (6)
2 (10)
1 (5)
13 (81)
16 (76)
15 (79)
3 (19)
2 (10)
2 (11)
12 (75)
16 (76)
14 (74)
3 (19)
2 (10)
2 (11)
4 (25)
8 (38)
5 (26)
4 (25)
2 (10)
2 (11)
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Figure 3 
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Figure Captions 
 
(Figure 1) 
6MWD for PAH patients by etiology. 
 
(Figure 2) 
Kaplan-Meier analysis of clinical worsening in PHIRST patients by etiology. 
 
(Figure 3) 
Kaplan-Meier analysis of time to clinical worsening of patients with I/H-PAH and patients 
with CTD-PAH treated with tadalafil 20 mg or 40 mg in the PHIRST and PHIRST-2 
studies. 
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Figure Legends 
(Figure 2) 
Abbreviations: TTCW = time to clinical worsening; PBO = placebo; I/H-PAH = idiopathic/heritable pulmonary arterial hypertension; 
CTD-PAH = pulmonary arterial hypertension associated with connective tissue disease; CW = clinical worsening  
N = total number of randomized subjects who have received study medication in the 3 treatment groups; n = number of subjects per 
category 
 (Figure 3) 
Abbreviations:  TTCW = time to clinical worsening; I/H-PAH = idiopathic/heritable pulmonary arterial hypertension; CTD-PAH = 
pulmonary arterial hypertension associated with connective tissue disease; CW = clinical worsening  
The tadalafil 20 and 40 mg treatment groups were combined for each subgroup 
N = total number of subjects in the tadalafil 20 and 40 mg treatment groups for the I/H=PAH and CTD-PAH subgroups; n = number 
of subjects per category 
